Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
In Vitro Drug Dissolution: Compendial Testing Models I01:13

In Vitro Drug Dissolution: Compendial Testing Models I

Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insight into human allogeneic CAR-T therapy: an open-access dataset.

Drug discovery today·2026
Same author

Development and Implementation of a Hinderance-based In Vitro Model for Porous Membranes.

The AAPS journal·2026
Same author

Relating plaque psoriasis barrier function changes with the underlying skin morphology and physiology.

Journal of pharmaceutical sciences·2026
Same author

Dataset of xenobiotics human renal clearance values.

Database : the journal of biological databases and curation·2026
Same author

Virtual Bioequivalence Assessment of Long-Acting Injectable Suspensions Using PBPK Modeling: Part 2. Type I Error and Safe Space Analyses.

The AAPS journal·2026
Same author

Virtual Bioequivalence Assessment of Long-acting Injectable Suspensions Using PBPK Modeling: Part 1. Impact of particle Size on Formulation Variability.

The AAPS journal·2026

Related Experiment Video

Updated: Jun 11, 2026

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
12:48

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

Published on: December 27, 2013

65.2K

Mechanistic Model for Drug Release from PLGA-Based Biodegradable Implants for In Vitro Release Testing: Development

Naresh Mittapelly1, Alexandre Djehizian1, Krishna Chaitanya Telaprolu1

  • 1Certara Predictive Technologies (CPT), Simcyp Division, Level 2-Acero, 1 Concourse Way, Sheffield S1 2BJ, U.K.

ACS Applied Bio Materials
|October 18, 2024
PubMed
Summary

A new mechanistic model predicts drug release from polylactide coglycolide (PLGA) implants by analyzing critical quality attributes and release processes. This model aids in optimizing PLGA formulation design for effective drug delivery.

Keywords:
PLGA-based solid implantsbiodegradable implantsin vitro release testinglong-acting injectablesmechanistic modeling

More Related Videos

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.2K
Direct and Indirect Culture Methods for Studying Biodegradable Implant Materials In Vitro
14:49

Direct and Indirect Culture Methods for Studying Biodegradable Implant Materials In Vitro

Published on: April 15, 2022

5.0K

Related Experiment Videos

Last Updated: Jun 11, 2026

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
12:48

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

Published on: December 27, 2013

65.2K
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.2K
Direct and Indirect Culture Methods for Studying Biodegradable Implant Materials In Vitro
14:49

Direct and Indirect Culture Methods for Studying Biodegradable Implant Materials In Vitro

Published on: April 15, 2022

5.0K

Area of Science:

  • Polymer science and drug delivery systems.
  • Biomaterials and pharmaceutical engineering.

Background:

  • Drug release from polylactide coglycolide (PLGA) formulations is influenced by numerous factors.
  • Understanding these factors is key to optimizing drug release profiles for specific applications.

Purpose of the Study:

  • To develop a mechanistic model for predicting *in vitro* drug release from PLGA-based solid implants.
  • To incorporate critical quality attributes (CQAs) and key release mechanisms into the model.

Main Methods:

  • Developed a mechanistic model for *in vitro* drug release from PLGA implants.
  • The model integrates polymer hydrolysis, drug dissolution, diffusion, and medium influx.
  • Validated the model using *in vitro* release data for four different drugs.

Main Results:

  • The model accurately accounts for critical quality attributes and release rate processes.
  • Validated model successfully predicted release profiles for buserelin, afamelanotide, brimonidine, and nafarelin implants.
  • Demonstrated the model's potential for optimizing PLGA formulation design.

Conclusions:

  • The developed mechanistic model offers valuable insights into drug release kinetics from PLGA implants.
  • Coupling this model with PBPK modeling can predict *in vivo* performance and support bioequivalence studies.